Epigenetic therapies of cancer

Current Cancer Therapy Reviews

Volumn 2, Issue 2, 2006, Pages 127-135

  Bootwala, Yasmin ^a   Bandyopadhyay, Debdutta ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

DNA methylation; DNA methyl transferase inhibitors; Epigenetics; Histone deacetylase inhibitors; Histone modification; SWI SNF complexes

Indexed keywords

3 PHENYLSULFAMOYLCINNAMOHYDROXAMIC ACID; 4 [N (2 HYDROXYETHYL) N [2 (3 INDOLYL)ETHYL]AMINOMETHYL]CINNAMOHYDROXAMIC ACID; 4 N ACETYLDINALINE; 5 AZA 2' DEOXYCYTIDINE; ADENOSINE TRIPHOSPHATE; ANACARDIC ACID; ANTISENSE OLIGONUCLEOTIDE; APICIDIN; AZACITIDINE; BUTYRIC ACID DERIVATIVE; COENZYME A; CURCUMIN; DEPSIPEPTIDE; DNA; EPIGALLOCATECHIN GALLATE; GEMCITABINE; HISTONE; HISTONE DEACETYLASE INHIBITOR; LYSINE; LYSYL COENZYME A; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; OXAMFLATIN; PROCAINAMIDE; PROCAINE; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ZEBULARINE;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; CELL AGING; CELL CYCLE; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN CONDENSATION; CHROMOSOME STRUCTURE; CLINICAL TRIAL; COVALENT BOND; CPG ISLAND; DNA METHYLATION; DNA MODIFICATION; DRUG TARGETING; EPIGENETICS; EUCHROMATIN; GENE REPRESSION; GENE SILENCING; GENE TARGETING; HETEROCHROMATIN; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; REGULATOR GENE; REVIEW; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 33746140967     PISSN: 15733947     EISSN: None     Source Type: Journal    
DOI: 10.2174/157339406776872816     Document Type: Review

References (95)

1. Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074-80.
2. Bandyopadhyay D, Timchenko N, Suwa T, Hornsby PJ, Campisi J, Medrano EE. The human melanocyte: a model system to study the complexity of cellular aging and transformation in non-fibroblastic cells. Exp Gerontol 2001; 36: 1265-75.
3. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004; 14: R546-R551.
4. Felsenfeld G, Groudine M. Controlling the double helix. Nature 2003; 421: 448-53.
5. Khorasanizadeh S. The nucleosome: from genomic organization to genomic regulation. Cell 2004; 116: 259-72.
6. Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998; 20: 615-26.
7. Varier RA, Swaminathan V, Balasubramanyam K, Kundu TK. Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem Pharmacol 2004; 68: 1215-20.
8. Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001; 1: 194-202.
9. Rea S, Eisenhaber F, O'Carroll D, et al. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 2000; 406: 593-9.
10. Sims RJ, III, Nishioka K, Reinberg D. Histone lysine methylation: a signature for chromatin function. Trends Genet 2003; 19: 629-39.
11. Feng Q, Wang H, Ng HH, et al. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol 2002; 12: 1052-8.
12. Cheung P, Lau P. Epigenetic regulation by histone methylation and histone variants. Mol Endocrinol 2005; 19: 563-73.
13. Shi Y, Lan F, Matson C, et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 2004; 119: 941-53.
14. Shi YJ, Matson C, Lan F, Iwase S, Baba T, Shi Y. Regulation of LSD1 histone demethylase activity by its associated factors. Mol Cell 2005; 19: 857-64.
15. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6-21.
16. Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16; 168-74.
17. Feinberg AP, Vogelstein B. Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 1983; 111: 47-54.
18. Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993; 82: 1820-8.
19. Oshimo Y, Nakayama H, Ito R, et al. Promoter methylation of cyclin D2 gene in gastric carcinoma. Int J Oncol 2003; 23: 1663-70.
20. Robertson KD. DNA methylation and chromatin - unraveling the tangled web. Oncogene 2002; 21: 5361-79.
21. Brueckner B, Lyko F. DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy. Trends Pharmacol Sci 2004; 25: 551-4.
22. Tate PH, Bird AP. Effects of DNA methylation on DNA-binding proteins and gene expression. Curr Opin Genet Dev 1993; 3: 226-31.
23. Prokhortchouk E, Hendrich B. Methyl-CpG binding proteins and cancer: are MeCpGs more important than MBDs? Oncogene 2002; 21: 5394-9.
24. Vignali M, Hassan AH, Neely KE, Workman JL. ATP-dependent chromatin-remodeling complexes. Mol Cell Biol 2000; 20: 1899-910.
25. Mohrmann L, Verrijzer CP. Composition and functional specificity of SWI2/ SNF2 class chromatin remodeling complexes. Biochim Biophys Acta 2005; 1681: 59-73.
26. Harikrishnan KN, Chow MZ, Baker EK, et al. Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing. Nat Genet 2005; 37: 254-64.
27. Borrow J, Stanton VP Jr, Andresen JM, et al. The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14: 33-41.
28. Giles RH, Dauwerse JG, Higgins C, et al. Detection of CBP rearrangements in acute myelogenous leukemia with t(8;16). Leukemia 1997; 11: 2087-96.
29. Muraoka M, Konishi M, Kikuchi-Yanoshita R, et al. p300 gene alterations in colorectal and gastric carcinomas. Oncogene 1996; 12: 1565-9.
30. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23: 4225-31.
31. Yao TP, Oh SP, Fuchs M, et al. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell 1998; 93: 361-72.
32. Yuan ZM, Huang Y, Ishiko T, et al. Function for p300 and not CBP in the apoptotic response to DNA damage. Oncogene 1999; 18: 5714-7.
33. Bandyopadhyay D, Okan NA, Bales E, Nascimento L, Cole PA, Medrano EE. Down-regulation of p300/CBP histone acetyltransferase activates a senescence checkpoint in human melanocytes. Cancer Res 2002; 62: 6231-9.
34. Pandolfi PP. Transcription therapy for cancer. Oncogene 2001; 20: 3116-27.
35. Dhordain P, Lin RJ, Quief S, et al. The LAZ3(BCL-6) oncoprotein recruits a SMRT/mSIN3A/histone deacetylase containing complex to mediate transcriptional repression. Nucleic Acids Res 1998; 26: 4645-51.
36. Wang J, Saunthararajah Y, Redner RL, Liu JM. Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 1999; 59: 2766-9.
37. Peters AH, O'Carroll D, Scherthan H, et al. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 2001; 107: 323-37.
38. Nielsen SJ, Schneider R, Bauer UM, et al. Rb targets histone H3 methylation and HP1 to promoters. Nature 2001; 412: 561-5.
39. Schneider R, Bannister AJ, Kouzarides T. Unsafe SETs: histone lysine methyltransferases and cancer. Trends Biochem Sci 2002; 27: 396-402.
40. Kim KC, Geng L, Huang S. Inactivation of a histone methyltransferase by mutations in human cancers. Cancer Res 2003; 63: 7619-23.
41. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-42.
42. Dowdy SC, Gostout BS, Shridhar V, et al. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines. Gynecol Oncol 2005;
43. Li J, El-Naggar A, Mao L. Promoter methylation of p16(INK4a), RASSF1A, and DAPK is frequent in salivary adenoid cystic carcinoma. Cancer 2005; 104: 771-6.
44. Frigola J, Munoz M, Clark SJ, Moreno V, Capella G, Peinado MA. Hypermethylation of the prostacyclin synthase (PTGIS) promoter is a frequent event in colorectal cancer and associated with aneuploidy. Oncogene 2005;
45. Qu GZ, Grundy PE, Narayan A, Ehrlich M. Frequent hypomethylation in Wilms tumors of pericentromeric DNA in chromosomes 1 and 16. Cancer Genet Cytogenet 1999; 109: 34-9.
46. Narayan A, Ji W, Zhang XY, et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 1998; 77: 833-8.
47. Qu G, Dubeau L, Narayan A, Yu MC, Ehrlich M. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 1999; 423: 91-101.
48. Widschwendter M, Jiang G, Woods C, et al. DNA hypomethylation and ovarian cancer biology. Cancer Res 2004; 64: 4472-80.
49. Wong N, Lam WC, Lai PB, Pang E, Lau WY, Johnson PJ. Hypomethylation of chromosome 1 heterochromatin DNA correlates with q-arm copy gain in human hepatocellular carcinoma. Am J Pathol 2001; 159: 465-71.
50. Hoffmann MJ, Schulz WA. Causes and consequences of DNA hypomethylation in human cancer. Biochem Cell Biol 2005; 83: 296-321.
51. Menendez L, Benigno BB, McDonald JF. L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer 2004; 3: 12.
52. Santourlidis S, Florl A, Ackermann R, Wirtz HC, and Schulz WA. High frequency of alterations in DNA methylation in adenocarcinoma of the prostate. Prostate 1999; 39: 166-74.
53. Khavari PA, Peterson CL, Tamkun JW, Mendel DB, Crabtree GR. BRG1 contains a conserved domain of the SWI2/SNF2 family necessary for normal mitotic growth and transcription. Nature 1993; 366: 170-4.
54. Reyes JC, Barra J, Muchardt C, Camus A, Babinet C, Yaniv M. Altered control of cellular proliferation in the absence of mammalian brahma (SNF2alpha). EMBO J 1998; 17: 6979-91.
55. Trouche D, Le CC, Muchardt C, Yaniv M, Kouzarides T. RB and hbrm cooperate to repress the activation functions of E2F1. Proc Natl Acad Sci USA 1997; 94: 11268-73.
56. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B. Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999; 59: 74-9.
57. Versteege I, Sevenet N, Lange J, et al. Truncating mutations of hSNF5/ INI1 in aggressive paediatric cancer. Nature 1998; 394: 203-6.
58. Oruetxebarria I, Venturini F, Kekarainen T, et al. P16INK4a is required for hSNF5 chromatin remodeler-induced cellular senescence in malignant rhabdoid tumor cells. J Biol Chem 2004; 279: 3807-16.
59. Geng F, Cao Y, Laurent BC. Essential roles of Snf5p in Snf-Swi chromatin remodeling in vivo. Mol Cell Biol 2001; 21: 4311-20.
60. Kalpana GV, Marmon S, Wang W, Crabtree GR, Goff SP. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. Science 1994; 266: 2002-6.
61. Wong AK, Shanahan F, Chen Y, et al. BRG1, a component of the SWI-SNF complex, is mutated in multiple human tumor cell lines. Cancer Res 2000; 60: 6171-7.
62. Loprevite M, Tiseo M, Grossi F, et al. In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines. Oncol Res 2005; 15: 39-48.
63. Saito A, Yamashita T, Mariko Y. et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999; 96: 4592-7.
64. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol Cancer Ther 2003; 2: 721-8.
65. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005; 40: 1-13.
66. Xiao H, Hasegawa T, Isobe K. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells. J Cell Biochem 1999; 73: 291-302.
67. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004; 101: 2760-70.
68. Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005; 25: 261-309.
69. Bandyopadhyay D, Mishra A, Medrano EE. Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway. Cancer Res 2004; 64: 7706-10.
70. Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2: 151-63.
71. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005; 45: 495-528.
72. Qian DZ, Wang X, Kachhap SK, et al. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res 2004; 64: 6626-34.
73. Liu LT, Chang HC, Chiang LC, Hung WC. Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 2003; 63: 3069-72.
74. Thompson PR, Kurooka H, Nakatani Y, Cole PA. Transcriptional coactivator protein p300. Kinetic characterization of its histone acetyltransferase activity. J Biol Chem 2001; 276: 33721-9.
75. Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/ CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004; 279: 51163-71.
76. Davidson SM, Townsend PA, Carroll C, et al. The transcriptional coactivator p300 plays a critical role in the hypertrophic and protective pathways induced by phenylephrine in cardiac cells but is specific to the hypertrophic effect of urocortin. Chembiochem 2005; 6: 162-70.
77. Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-45.
78. Butler LM, Agus DB, Scher HI, et al. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 2000; 60: 5165-70.
79. Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003; 4: 13-8.
80. Marks PA, Richon VM, Rifkind RA. Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 2000; 92: 1210-6.
81. Ungerstedt JS, Sowa Y, Xu WS, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102: 673-8.
82. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-6.
83. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004; 429: 457-63.
84. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004; 103: 1635-40.
85. Cheng JC, Matsen CB, Gonzales FA, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 2003; 95: 399-409.
86. Villar-Garea A, Fraga MF, Espada J, Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 2003; 63: 4984-9.
87. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-70.
88. Yan L, Nass SJ, Smith D, Nelson WG, Herman JG, Davidson NE. Specific inhibition of DNMT1 by antisense oligonucleotides induces re-expression of estrogen receptor-alpha (ER) in ER-negative human breast cancer cell lines. Cancer Biol Ther 2003; 2: 552-6.
89. Zhu WG, Lakshmanan RR, Beal MD, Otterson GA. DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 2001; 61: 1327-33.
90. Belinsky SA, Klinge DM, Stidley CA, et al. Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. Cancer Res 2003; 63: 7089-93.
91. Cameron EE, Bachman KE, Myohanen S. Herman JG, Baylin SB. Synergy of demethylation and historic deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103-7.
92. Primeau M, Gagnon J, Momparler RL. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2′-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 2003; 103: 177-84.
93. Dasmahapatra G, Almenara J, Grant S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells overexpressing BCL-2. Mol Pharmacol 2006; 69: 288-98.
94. Rosato RR, Almenara JA, Yu C, Grant S. Evidence of a functional role for p21WAF1/CIP1 down-regulation in synergistic antileukemic interactions between the histone deacetylase inhibitor sodium butyrate and flavopiridol. Mol Pharmacol 2004; 65: 571-81.
95. Rosato RR, Grant S. Histone deacetylase inhibitors in clinical development. Expert Opin Investig Drugs 2004; 13: 21-38.